Separate terms with OR to return results that match either term.
 
Clear All

10,000 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class (Ascending) Administration Route Package Effective Date Package Discontinuation Date Status
00078-0668-15 00078-0668 Trametinib Mekinist 2.0 mg/1 Chemotherapy MEK Inhibitor BRAF Oral March 17, 2016 April 30, 2024 In Use
00078-0666-15 00078-0666 Trametinib Mekinist 0.5 mg/1 Chemotherapy MEK Inhibitor BRAF Oral March 17, 2016 Oct. 31, 2023 No Longer Used
50242-0090-01 50242-0090 Vemurafenib Zelboraf 240.0 mg/1 Chemotherapy Enzyme Inhibitor BRAF Oral Aug. 17, 2011 Feb. 28, 2018 In Use
50242-0090-02 50242-0090 Vemurafenib Zelboraf 240.0 mg/1 Chemotherapy Enzyme Inhibitor BRAF Oral Sept. 8, 2015 In Use
50242-0090-86 50242-0090 Vemurafenib Zelboraf 240.0 mg/1 Chemotherapy Enzyme Inhibitor BRAF Oral April 10, 2014 In Use
00002-6902-30 00002-6902 Pirtobrutinib JAYPIRCA 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BTK Oral Jan. 27, 2023 In Use
72579-0011-01 72579-0011 Zanubrutinib BRUKINSA 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BTK Oral Nov. 14, 2019 Sept. 30, 2021 In Use
72579-0011-02 72579-0011 Zanubrutinib BRUKINSA 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BTK Oral Nov. 14, 2019 In Use
00310-3512-60 00310-3512 Acalabrutinib CALQUENCE 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BTK Oral Aug. 4, 2022 In Use
00310-3512-95 00310-3512 Acalabrutinib CALQUENCE 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BTK Oral Aug. 4, 2022 In Use
00002-7026-60 00002-7026 Pirtobrutinib JAYPIRCA 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BTK Oral Jan. 27, 2023 In Use
00002-7026-99 00002-7026 Pirtobrutinib JAYPIRCA 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BTK Oral Feb. 15, 2023 In Use
00310-0512-28 00310-0512 Acalabrutinib Calquence 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BTK Oral April 1, 2018 July 31, 2021 In Use
00310-0512-60 00310-0512 Acalabrutinib Calquence 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BTK Oral Oct. 31, 2017 In Use
00310-0512-95 00310-0512 Acalabrutinib Calquence 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BTK Oral April 1, 2020 July 31, 2025 In Use
54482-0053-01 54482-0053 Procarbazine Hydrochloride Matulane 50.0 mg/1 Chemotherapy Alkylating Agent Benzamide Oral Dec. 27, 1985 March 31, 2020 No Longer Used
57962-0014-28 57962-0014 Ibrutinib IMBRUVICA 140.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor Bruton's Tyrosine Kinase (Btk) /BCR Oral Feb. 16, 2018 In Use
57962-0070-28 57962-0070 Ibrutinib IMBRUVICA 70.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor Bruton's Tyrosine Kinase (Btk) /BCR Oral Dec. 20, 2017 In Use
57962-0140-09 57962-0140 Ibrutinib Imbruvica 140.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor Bruton's Tyrosine Kinase (Btk) /BCR Oral Nov. 13, 2013 In Use
57962-0140-12 57962-0140 Ibrutinib Imbruvica 140.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor Bruton's Tyrosine Kinase (Btk) /BCR Oral Nov. 13, 2013 In Use
57962-0280-28 57962-0280 Ibrutinib IMBRUVICA 280.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor Bruton's Tyrosine Kinase (Btk) /BCR Oral Feb. 16, 2018 In Use
57962-0420-28 57962-0420 Ibrutinib IMBRUVICA 420.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor Bruton's Tyrosine Kinase (Btk) /BCR Oral Feb. 16, 2018 In Use
57962-0420-71 57962-0420 Ibrutinib IMBRUVICA 420.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor Bruton's Tyrosine Kinase (Btk) /BCR Oral Feb. 6, 2019 In Use
57962-0007-12 57962-0007 Ibrutinib Imbruvica 70.0 mg/mL Chemotherapy Tyrosine Kinase Inhibitor Bruton's Tyrosine Kinase (Btk) /BCR Oral Aug. 24, 2022 In Use
57962-0560-28 57962-0560 Ibrutinib IMBRUVICA 560.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor Bruton's Tyrosine Kinase (Btk) /BCR Oral Feb. 16, 2018 Feb. 28, 2025 In Use

Found 10,000 results in 7 millisecondsExport these results